POC System that Requires Single DNA Molecule for Rapid Detection of Multidrug-Resistant Pathogens Unveiled at MEDICA 2021
|
By LabMedica International staff writers Posted on 18 Nov 2021 |

A new compact device for detecting multidrug-resistant pathogens that performs all stages of the reaction automatically and provides a result within one hour using one single DNA molecule was unveiled at MEDICA 2021.
Researchers at the Fraunhofer Institute for Physical Measurement Techniques IPM (Freiburg, Germany) alongside the Ludwig Maximilian University of Munich (Munich, Germany) have developed a process for rapidly detecting multidrug-resistant pathogens. The unique feature: Even one single molecule of DNA is sufficient for pathogen detection. In future, the platform could be introduced as part of point-of-care diagnostics on hospital wards or in medical practices as an alternative to the established PCR analyses or in combination with other diagnostic methods.
Choosing the correct antibiotic to treat bacterial infections is a deciding factor when it comes to the success of a treatment. It is particularly difficult to select suitable medication in cases where a disease is caused by multidrug-resistant pathogens, which are unaffected by many antibiotics. Searching for the most effective antibiotic often requires information about the bacteria’s genome. Most of the time, this information is not readily available at medical practices and can only be obtained through a laboratory diagnosis. To accelerate and simplify the process, the researchers developed a new platform for detecting pathogens on the basis of single molecules on a microfluidic chip. The focus of the SiBoF (signal boosters for fluorescence assays in molecular diagnostics) project lies on an easy-to-use point-of-care (POC) detection method.
The portable, compact test platform is equipped with an automated fluidic system. All necessary reagents are stored within the system. The injection-molded microfluidic chip is incorporated in a drawer in the test system, where it is supplied with the reagents through the fluidics system before the optical analysis takes place. Typically, target DNA molecules are detected by means of specific fluorescence markers. A unique feature of the new method is that researchers are utilizing antennas with nanometer-sized beads, which amplify the optical signals of these markers. Because of this, chemical amplification via polymerase chain reaction (PCR) is not required.
A structure of DNA molecules, known as “DNA origami”, which was specifically designed by the Ludwig Maximilian University of Munich, holds both of the gold nanoparticles in place. Between these nanoparticles, the structure provides a binding site for the respective target molecule and a fluorescence marker. This patented design provides the basis for the novel assay technology. Low concentrations of pathogens can be detected. The result is available after one hour and is displayed on the monitor. This is not only true for multidrug-resistant pathogens, but also for any type of DNA molecule. In principle, the single molecule assay can be adapted to molecules beyond DNA, such as RNA, antibodies, antigens or enzymes. Numerous tests have successfully confirmed the functionality of the process. At the heart of the POC device is a miniaturized high-resolution fluorescence microscope, developed by Fraunhofer IPM. Specifically developed image analysis software identifies single molecules and by doing so enables the captured target molecules to be counted, providing a quantitative result. The fluorescence is stimulated using LEDs, which are affixed underneath the cartridge containing the fluidic channels.
“We detect part of the pathogen’s DNA strand. Using our new process, even a single molecule of DNA that binds to a specific site on the microfluidic chip is sufficient to do this. Fluidic channels are integrated into the chip – the surfaces of which are primed with binding sites for specific pathogens,” explained Dr. Benedikt Hauer, scientist at Fraunhofer IPM.
Related Links:
Fraunhofer Institute for Physical Measurement Techniques IPM
Ludwig Maximilian University of Munich
Latest Pathology News
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
Accurate identification of Alzheimer’s disease pathology often relies on cerebrospinal fluid analysis or positron emission tomography, which can be invasive, costly, and not widely accessible.... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Genetic Testing Identifies High-Risk Patients with Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is a lifelong, unpredictable condition that can require advanced therapies or surgery. More than half a million people in the U.... Read more
Ancestry-Informed Genomics Advances Precision Cancer Prognosis
Predicting survival in common cancers remains imprecise despite widespread use of tumor sequencing to guide care. Outcome disparities among patient populations also persist, and the genomic drivers behind... Read more
New Blood Test Predicts Organ-Specific Disease and Mortality Years in Advance
Quantifying organ-specific aging remains a diagnostic challenge, even as age-related disorders drive morbidity and mortality worldwide. Chronological age poorly reflects the physiologic decline that predisposes... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








